Abelacimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Abelacimab
- abelacimab
- Abelacimab
- abelacimab [INN]
- ABELACIMAB [USAN]
- Abelacimab [WHO-DD]
- abelacimab inn
- abelacimab usan
- abelacimab who dd
- immunoglobulin g1 anti human blood coagulation factor xi human monoclonal clone nvs250519 gamma 1 chain disulfide with human monoclonal nvs250519 lambda chain dimer
- immunoglobulin g1 lambda anti homo sapiens f11 coagulation factor xi fxi plasma thromboplastin antecedent pta homo sapiens monoclonal antibody gamma1 heavy chain 1 452 homo sapiens vh ighv3 23 01 93 9 ighd ighj4 01 100 8 8 15 1 122 homo sapiens ighg1 03 g1m3 ng1m1 ch1 r120 219 123 220 hinge 221 235 ch2 d27 a 270 p114 a 334 236 345 ch3 e12 361 m14 363 346 450 chs 451 452 123 452 225 215 disulfide with lambda light chain 1 216 homo sapiens v lambda iglv1 44 01 93 5 iglj2 01 100 8 3 11 1 110 homo sapiens iglc2 01 111 216 dimer 231 231 234 234 bisdisulfide
- immunoglobulin G1-lambda, anti-[Homo sapiens F11 (coagulation factor XI, FXI, plasma thromboplastin antecedent, PTA)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-452) [Homo sapiens VH (IGHV3-23*01 (93.9%) -(IGHD) IGHJ4*01 (100%)) [8.8.15] (1-122) -Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (219) (123-220), hinge (221-235), CH2 D27>A (270), P114>A (334) (236-345), CH3 E12 (361), M14 (363) (346-450), CHS (451-452)) (123-452)], (225-215')disulfide with lambda light chain (1'-216') [Homo sapiens V-LAMBDA (IGLV1-44*01 (93.5%) -IGLJ2*01 (100%)) [8.3.11] (1'-110') -Homo sapiens IGLC2*01 (111'-216')]; dimer (231-231'':234-234'')-bisdisulfide
- IMMUNOGLOBULIN G1, ANTI-(HUMAN BLOOD-COAGULATION FACTOR XI) (HUMAN MONOCLONAL CLONE NVS250519 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL NVS250519 .LAMBDA.-CHAIN, DIMER
- nvp maa868
- NVP-MAA868
- CAS registry numbers
- 2098724-83-3
- ChEMBL ID
- CHEMBL4650369
- FDA ingredient codes (UNII)
- KX1N4TV7UY
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- abelacimab
- Type
- Antibody
- Drug name stem
- -mab
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- coagulation factor XI
- Gene symbol
- F11
- Protein identifier
- P03951
- Median affinity
- 11.89
- Affinity units
- pKd
- Mechanism
- Coagulation factor XI inhibitor
- Action type
- Inhibitor
- Target
- Coagulation factor XI
- Protein identifier
- P03951
Open Targets mechanisms
- Mechanism
- Coagulation factor XI inhibitor
- Action type
- Inhibitor
- Target
- Coagulation factor XI
- Condition
- Atrial Fibrillation
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000275
- Subject identifier
- D001281
- Condition
- Venous Thromboembolism
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004286
- Subject identifier
- D054556
- Condition identifier
- EFO_0000275
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004981
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005399
- Highest recorded phase
- 3
- Condition identifier
- MP_0001914
- Highest recorded phase
- 3
- NCT05171049
- NCT05171075
- NCT05712200
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (5)
- A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
- A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
- Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
- Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation
- Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
In development for (2)
- Atrial fibrillation Phase 3
- Venous thromboembolism Phase 3
Targets (1)
- F11 Coagulation factor XI inhibitor